What is Replimune?
Replimune Group is a clinical-stage biotechnology company dedicated to the development of next-generation oncolytic immunotherapies. The company focuses on engineering viruses that selectively replicate within tumor cells, thereby triggering a robust and durable immune response against cancer. By integrating advanced molecular biology with patient-specific treatment modalities, Replimune aims to improve the potency and efficacy of existing immunotherapy standards. Its market position is defined by a rigorous focus on scientific innovation and the translation of complex biological mechanisms into scalable, life-changing medical solutions for patients with high unmet needs.
How much funding has Replimune raised?
Replimune has raised a total of $526M across 5 funding rounds:
Series A
$30M
Series B
$55M
Stock Offering
$111M
Stock Offering
$80M
Stock Offering
$100M
Series A (2015): $30M with participation from Atlas Ventures, Omega Funds, and Forbion
Series B (2017): $55M led by Foresite Capital, Omega Funds, Forbion, Bain Capital, Redmile Group, Leerink Partners, Cormorant Asset Management, and Atlas Venture
Stock Issuance/Offering (2018): $111M supported by Undisclosed
Stock Issuance/Offering (2019): $80M featuring Undisclosed
Stock Issuance/Offering (2020): $100M backed by Undisclosed
Key Investors in Replimune
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Omega Funds
Omega Funds is a specialized investment firm that provides capital and strategic guidance to innovative life sciences companies throughout their development lifecycle.
Forbion
Forbion is a global life sciences venture capital firm with a strong track record of sourcing, building, and guiding biotech and biopharmaceutical companies from early stage through clinical development.
What's next for Replimune?
With the infusion of capital from its most recent financing, Replimune is well-positioned to accelerate its clinical trial programs and expand its manufacturing capabilities. The strategic focus will likely shift toward optimizing the delivery of its lead candidates and exploring combination therapies that could redefine standard-of-care protocols in oncology. As the company matures, the emphasis will remain on achieving key clinical readouts that validate its platform's potential to drive long-term value for stakeholders and patients alike. Future growth will be contingent upon the successful execution of its pipeline, regulatory milestones, and the continued support of its sophisticated investor base.
See full Replimune company page
